PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can ...

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional Office in San Francisco, a major HIV drug maker ...

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...

– Investigational Long-Acting, Twice-Yearly Treatment Regimen of Lenacapavir and Broadly Neutralizing Antibodies (bNAbs) Meets Primary Endpoint in Phase 2 Study and Gains Breakthrough Therapy ...